Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EFL 200

Next Previous
Search
Drug Profile

EFL 200

Alternative Names: EFL-200

Latest Information Update: 23 Nov 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iNtRON Biotechnology
  • Class Antibacterials; Endolysins; Proteins
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Vancomycin-resistant enterococcal infections

Most Recent Events

  • 19 Nov 2018 Tonabacase (SAL200), anti-vancomycin-resistant enterococcal and anti-tuberculosis biologics licensed to Roivant Sciences
  • 05 Aug 2016 Investigation in Vancomycin-resistant enterococcal infections in South Korea (unspecified route)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top